Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy

Cancer Journal

Volumn 6, Issue 3, 2000, Pages 157-161

  Hesketh, Paul J ^a   Crews, Jennie R ^b   Cohen, Roger ^c   Blackburn, Linda M ^d   Friedman, Carl J ^d  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b Raleigh Psychiatric Associates   (United States)

^c UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Carboplatin; Cyclophosphamide; Dexamethasone; Granisetron; Methyl prednisolone; Nausea; Vomiting

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANISETRON; METHYLPREDNISOLONE;

ARTICLE; CANCER INHIBITION; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEADACHE; HUMAN; INSOMNIA; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; ALCOHOL DRINKING; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; GRANISETRON; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; NAUSEA; NEOPLASMS; SEROTONIN ANTAGONISTS; SEX FACTORS;

EID: 0033913701     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Reynolds DJM, Andrews PLR, Davis CJ, eds. Serotonin and the Scientific Basis of Anti-Emetic Therapy. Oxford, UK: Oxford Clinical Communications, 1995.
2. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. Drugs 1998;55:173-189.
3. Andrews PL, Bhandari P, Davey PT et al. Are all 5-HT3 receptor antagonists the same? Eur J Cancer 1992;28A[suppl 1]:S2-6.
4. Perez EA. A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis. Drug Saf 1998;18:43-56.
5. Hesketh P, Navari R, Grote T et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-Induced Emesis Prevention Group. J Clin Oncol 1996;14:2242-2249.
6. Audhuy B, Cappelaere P, Martin M et al. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996;32A:807-813.
7. Fauser AA, Duclos B, Chemaissani A et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetran Comparative Study Group. Eur J Cancer 1996;32A:1523-1529.
8. Perez EA, Hesketh P, Sandbach J et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 1998;16:754-760.
9. Gralla RJ, Navari RM, Hesketh PJ et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998;16:1568-1573.
10. Navari R, Gandara D, Hesketh P et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. Granisetron Study Group. J Clin Oncol 1995;13:1242-1248.
11. NCCN antiemesis practice guidelines. NCCN Proceedings. Oncology (Huntingt) 1997;11(Nov):57-89.
12. Italian Group for Antiemeric Research. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol 1995;13:2417-2426.
13. Ruff P, Paska W, Goedhals L et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Ondansetron and Granisetron Emesis Study Group. Oncology 1994;51(Jan-Feb):113-118.
14. Noble A, Bremer K, Goedhals L et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Granisetron Study Group. Eur J Cancer 1994;30A:1083-1088.
15. Gebbia V, Cannata G, Testa A et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer 1994;74:1945-1952.
16. Beck TM, Hesketh PJ, Madajewicz S et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992;10:1969-1975.
17. Abang AM, Takemoto MH, Pham T et al. A randomized, double-blind, pilot study comparing the efficacy and safety of oral (PO) granisetron to intravenous (IV) granisetron in patients undergoing peripheral blood stem cell (PBSCT) and bone marrow transplantation (BMT) [abstract]. Proc Am Soc Clin Oncol 1998;17:52a.
18. Perez EA. Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis. Clin Ther 1996;18:578-590.
19. Krzakowski M, Graham E, Goedhals L et al. A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Anti-Cancer Drugs 1998;9:593-598.
20. 3 receptor antagonism in the control of cytostaric drug-induced emesis. Eur J Cancer 1990;26[suppl 1]:S8-11.
21. Burris H, Hesketh P, Cohn J et al. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 1996;2:85-90.
22. Ettinger DS, Eisenberg PD, Fitts D et al. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer 1996;78:144-151.
23. Bleiberg HH, Spielmann M, Falkson G et al. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study. Clin Ther 1995;17:38-51.
24. 3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin. Oncol Rep 1998;5:273-280.
25. Goedhals L, Heron J-F, Kleisbauer J-P et al. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann Oncol 1998;9:661-666.
26. Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 1997;15:124-130.
27. Gebbia V, Testa A, Valenza R et al. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. Cancer 1995;76:1821-1828.
28. Martoni A, Angelelli B, Guaraldi M et al. Granisetron (GRA) vs. ondansetron (OND) in the prevention of cis-platinum-induced emesis: an open randomized cross-over study [abstract]. Proc Am Soc Clin Oncol 1994;13:431.
29. Beck TM, Ciociola AA, Jones SE et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ondansetron Study Group. Ann Intern Med 1993;118:407-413.
30. Rubenstein EB, Gralla RJ, Hainsworth JD et al. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Cancer 1997;79:1216-1224.
31. Navari RM, Kaplan HG, Gralla RJ et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994;12:2204-2210.
32. Grote T, Rubenstein E, Fauser AA. Equivalence of 100 mg oral dolasetron (DOL) and multiple oral doses of ondansetron (OND) in patients receiving moderately emetogenic chemotherapy (MEC) [abstract]. Proc Am Soc Clin Oncol Annu Meet 1998;17:45a.
33. Grote TH, Pineda LF, Figlin RA et al. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group. Cancer J Sci Am 1997;3:45-51.
34. Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995;13:1036-1043.
35. Roila F, Tonato M, Basurto C et al. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine. A study of the Italian Oncology Group for Clinical Research. J Clin Oncol 1989;7:1693-1700.
36. 3 receptor antagonists. Support Care Cancer 1994;2:286-292.